Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-10-15 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2024年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2024 fifth extraordinary general meeting of shareholders. It details the meeting date, attendance, voting results on specific proposals, and legal compliance statements. It does not contain financial statements or detailed financial analysis but rather the official voting results and meeting procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1934 characters), and it is not merely announcing the availability of a report but providing the voting results themselves. Therefore, the correct classification is DVA.
2024-10-15 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2024年第五次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, and voting procedures of KunYao Group Co., Ltd.'s 2024 fifth extraordinary general meeting of shareholders. It details the legality and validity of the meeting's process and resolutions passed. The document does not contain financial statements or results but focuses on the legal compliance and procedural aspects of a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the voting results and legitimacy of the shareholder meeting resolutions.
2024-10-15 Chinese
昆药集团2024年第五次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2024 Fifth Extraordinary General Meeting (EGM) Meeting Materials" of KPC Pharmaceuticals, Inc. It contains detailed agenda, meeting procedures, and two main proposals for shareholder approval: (1) the appointment of the 2024 annual audit firm (KPMG Huazhen) and (2) the use of idle funds for investment and wealth management. The document includes detailed explanations of the proposals, voting procedures, and legal compliance notes. It is clearly a set of materials prepared for a shareholders' meeting, not a report itself. The content is consistent with materials typically provided for an Extraordinary General Meeting (EGM) or Annual General Meeting (AGM) to inform shareholders and facilitate voting. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or EGM. The document length (8255 characters) and detailed content confirm it is the meeting materials, not just an announcement or a brief notice. Hence, the classification is AGM-R with high confidence.
2024-10-08 Chinese
昆药集团十届三十二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various company management and policy matters, including investment, guarantee management, debt management, salary management, and scheduling a shareholders' meeting. The document is titled as a board meeting resolution announcement and includes voting outcomes by the board members. It does not contain financial statements, earnings data, or detailed management discussion. It is not a full annual or interim report, nor an earnings release or investor presentation. It is not a proxy solicitation or voting results announcement from a shareholder meeting but rather a board/management information disclosure. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on board resolutions, consistent with MANG filings.
2024-09-27 Chinese
昆药集团关于召开公司2024年第五次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 fifth extraordinary general meeting of shareholders for Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization. It does not contain financial statements, audit reports, or detailed financial data. It is an announcement related to a shareholders' meeting rather than the meeting materials or results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document is under 5,000 characters and is a notice for a meeting, not a report or results announcement, so it is not a Report Publication Announcement or Declaration of Voting Results.
2024-09-27 Chinese
昆药集团关于利用闲置自有资金进行投资理财业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of idle funds for investment in financial products. It details the board and supervisory committee approvals, investment scope, risk analysis, and the need for shareholder approval. The document is a formal announcement of a financing-related decision and authorization, not a financial report or earnings release. It does not contain financial statements or detailed financial data but rather informs shareholders and the market about a capital management decision. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2071 characters, which is consistent with an announcement rather than a full report.
2024-09-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.